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Abstract
Background: Low-dose methotrexate (MTX) is the first-line therapy in early rheumatoid arthritis (eRA). Up to 40% of
eRA patients do not benefit from MTX therapy. MTX has been shown to inhibit one-carbon metabolism, which is
involved in the donation of methyl groups. In this study, we investigate baseline global DNA methylation and
changes in DNA methylation during treatment in relation to clinical non-response after 3 months of MTX treatment.
Methods: Two hundred ninety-four blood samples were collected from the Treatment in the Rotterdam Early Arthritis
Cohort (tREACH, ISRCTN26791028), a multicenter, stratified single-blind clinical trial of eRA patients. Global DNA (hydroxy)
methylation was quantified using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/
MS) and validated with a global DNA LINE-1 methylation technique. MTX response was determined as ΔDAS28.
Additionally, patients were stratified into two response groups according to the European League Against Rheumatism
(EULAR) response criteria. Associations between global DNA methylation and response were examined using univariate
regression models adjusted for baseline DAS28, baseline erythrocyte folate levels, and body mass index (BMI).
Results: Higher baseline global DNA methylation was associated with less decrease of DAS28 (β= 0.15, p = 0.013) and
with MTX non-response (OR = 0.010, 95% CI = 0.001–0.188). This result was validated in LINE-1 elements (β = 0.22, p =
0.026). Changes in global DNA (hydroxy)methylation were not associated with MTX response over 3months.
Conclusions: These results show that higher baseline global DNA methylation in treatment naïve eRA patients
is associated with decreased clinical response after 3 months of treatment of eRA patients and can be further
evaluated as a predictor for MTX therapy non-response.
Trial registration: ISRCTN, ISRCTN26791028, registered 23 August 2007—retrospectively registered
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Background
Rheumatoid arthritis (RA) is an autoimmune disease affect-
ing about 1% of the world’s population [1]. The disease
onset is unknown; nevertheless, medication can restrain
disease activity and permanent joint damage. The disease-
modifying anti-rheumatic drug (DMARD) methotrexate
(MTX) is the first-line therapy in early rheumatoid arthritis
(eRA) [2] and is often prescribed in combination with
sulfasalazine (SSZ), hydroxychloroquine (HCQ), and corti-
costeroids. Up to 40% of treated patients do not adequately
respond to therapy and need to switch to expensive biolog-
icals after 3 to 6months of therapy, or withdraw because of
severe adverse events [3]. Therefore, new biomarkers are
required to distinguish non-responders prior to treatment.
MTX is a folate antagonist of which the underlying
mechanism in RA is still not fully elucidated. MTX was
originally designed for cancer therapy to inhibit DNA syn-
thesis by inhibiting key intracellular enzymes in folate me-
tabolism. These include dihydrofolate reductase (DHFR)
and thymidylate synthase (TS). The anti-inflammatory
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mechanism of action of low-dose MTX treatment
used in eRA probably relates to the inhibition of key
enzymes in the purine de novo synthesis pathway and
release of anti-inflammatory adenosine [4]. MTX also
inhibits methionine S-adenosyltransferase (MAT),
followed by the inhibition of S-adenosyl methionine
(SAM) in vivo and in vitro [5, 6]. SAM is responsible
for the donation of methyl groups required for global
DNA methylation. MTX is therefore hypothesized to
inhibit global DNA methylation, although elevated
global DNA methylation was observed in peripheral
blood mononuclear cells (PBMCs) of MTX-treated
patients [7]. If the effect of MTX is related to a
decrease in global DNA methylation through inhib-
ition of MAT and SAM, then we hypothesize that
higher baseline global DNA methylation might be
more difficult to inhibit and therefore affects MTX
responsiveness.
In the current prospective study, we investigated
whether higher baseline global DNA (hydroxy)methyla-
tion in leukocytes of early RA patients is associated with
MTX clinical non-response over the first 3 months of
treatment. Furthermore, we assessed whether a lesser
decrease in global DNA methylation during treatment
or higher global DNA methylation at 3 months of
MTX treatment was associated with MTX clinical
non-response.
Materials and methods
Subjects and samples
Four hundred ninety-six subjects were eligible from the
Treatment in the Rotterdam Early Arthritis Cohort
(tREACH, ISRCTN26791028), a multicenter, stratified
single-blind, randomized controlled trial of eRA patients,
as previously described [8]. In brief, included patients
were diagnosed with RA based on the American College
of Rheumatology (ACR) 1987 classification criteria for
RA [9] and were categorized in high, intermediate, or
low probability groups for persistent disease, according
to the Visser prediction model [10]. All patients who
received MTX mono or combination (MTX + cortico-
steroids and MTX + SSZ + HCQ + corticosteroids) ther-
apy were enrolled in this study (n = 336). An escalating
dose of MTX was prescribed in the first 3 weeks from
10mg (week 1) up to 17.5 mg (week 2) and 25mg (week
3). Additionally, all patients received weekly 10 mg folic
acid, at least 24 h after MTX administration, as recom-
mended [2]. Whole blood leukocytes were collected at
baseline (T0) and after 3 months of MTX therapy (T3)
and stored at − 80 °C. This study was approved by the
medical ethics committee of the Erasmus University
Medical Center: MEC-2006-252. Medical ethics com-
mittees at each participating center approved the study
protocol, and written informed consent was obtained
for all patients.
LC-ESI-MS/MS
DNA digestion
Genomic DNA was isolated using the MagNA Pure
Compact Nucleic Acid Isolation Kit (Roche Molecular
Biochemicals®) according to the manufacturer’s instruc-
tions. DNA concentration was quantified using a Nano-
Drop ND-1000 Spectrophotometer with DNA-50 default
settings (NanoDrop Technologies), and 260/280 ratios
~ 1.8 were considered pure DNA. Samples were stored
at − 80 °C and diluted to 30 ng/μl 1 day prior to the
start of the experiment. Six hundred nanograms of gen-
omic DNA was added to the following digestion mix-
ture: 1 μl DNA Degradase Plus™ enzyme (5 U/ml, Zymo
Research®), 2.5 μl 10× DNA Degradase Reaction Buffer,
and 1.5 μl Milli-Q, with a total reaction volume of 25 μl.
The samples were centrifuged for 1 min at 3100 rpm
and placed in a Thermo Mixer®C (Eppendorf ) for 5 h at
37 °C, followed by an enzyme heat inactivation step for
20 min at 70 °C.
Quantification of global DNA (hydroxy)methylation
Following DNA degradation, the 25 μl reaction vol-
ume was 1:1 diluted with an Internal Standard mix-
ture (IS, 19.2 nM 5-hmdc-d3, 205 nM 5-mdc-d3,
1.84 μM 2-dG-15N5). A calibration curve was made as
follows: for each component, a calibrator was diluted
to a final concentration of 10 nM (5-hmdC), 1000 nM
(5-mdC), and 20,000 nM (2-dG), which were then
serially 1:1 diluted to 0 in 5 steps. Of each dilution,
400 μl was added to 600 μl of diluted IS. Global DNA
methylation and hydroxymethylation were measured
using liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS) in the
positive ionization mode. Twenty microliters was
injected on a T3-high strength silica column (Acquity
UPLC®, Waters, C18, 2.1 × 100 mm, 1.8 μm) at 35 °C.
0.1% formic acid in Milli-Q (A), and acetonitrile (B)
was used as the mobile phase at a flow rate of 0.20
ml/min. The following gradient was used: 0–0.5 min
(98% A and 2% B), 5 min (0% A and 100% B), 5.50
min (0% A and 100% B), 5.51 min (98% A and 2% B),
and 7 min (98%A and 2%B), where all gradient steps
were linear. An aliquoted DNA sample was measured
as quality control (QC) in every run to uncover
potential errors during sample preparation and DNA
(hydroxy)methylation quantification. The coefficient of
variation (%CV) was calculated from all the QC
measurements (n = 24) and was 2.4% for methylation
and 7.7% for hydroxymethylation measurements. The
percentage of (hydroxy)methylation was calculated in
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relation to the total guanine concentration, using the
following formulas:
%5mdC ¼ nM 5mdC=nM 2−dGð Þ  100
%5hmdC ¼ nM 5hmdC=nM 2−dGð Þ  100
Sequenom EpiTYPER LINE-1 assay
LINE-1 global DNA methylation was determined in
DNA from leukocytes, isolated using the Sequenom Epi-
TYPER® assay (Agena Bioscience™) as previously de-
scribed [11, 12]. Briefly, 500 ng of purified genomic
DNA was treated with sodium bisulfite to distinguish
methylated from non-methylation cytosines using the
EZ DNA MethylationTM Kit (Zymo Research®) accord-
ing to the manufacturer’s instructions. Converted DNA
concentrations were quantified using a ND-1000 Nano-
Drop Spectrophotometer (NanoDrop Technologies Inc.)
using the RNA-40 default settings, as recommended (Zymo
Research®). Bisulfite-converted DNA was stored no longer
than 1month at − 80 °C or until the experiment was per-
formed. A LINE-1 bisulfite-targeted PCR was performed
on the C-1000 Touch Thermal Cycler™ (Bio-Rad) using the
following primers: 5′aggaagagagGTGTGAGGTGTTAGTG
TGTTTTGTT-3′ and 3′cagtaatacgactcactatagggaggaaggct
ATATCCCACACCTAACTCAAAAAAT-′5. The PCR was
followed by Shrimp Alkaline Phosphatase treatment, RNA
transcription, and Sequenom analysis as previously de-
scribed [12]. A mixture consisting of 100% enzymatically
methylated DNA and 0% methylated DNA, due to a genetic
knockout for methyltransferases, resulted in 50% DNA
methylation and was used as a positive control during all
steps. Milli-Q water was used as a negative control. DNA
methylation was quantified using a Matrix-assisted Laser
Desorption/Ionization-Time Of Flight (MALDI-TOF) Mas-
sARRAY® (Sequenom) analyzer according to the manufac-
turer’s instructions. Methylation percentage was calculated
using the following formula: % Methylation = (area methy-
late peak)/(area unmethylated peak + area methylated peak)
× 100. All samples were measured in triplet and samples
with a variation coefficient (CV) of > 10% were checked for
outliers by means of Dixon’s Q test. Outliers were removed,
and if CV still exceeded 10% for the remaining duplicate,
the sample was excluded. Twelve CpG sites were present
within the LINE-1 PCR fragment of which CpG 6.7, CpG
8.9, and CpG 11.12 were combined, since these sites could
not be separated. CpG 4 could not be analyzed because
of a silent signal, and CpG 10 could not be analyzed
due to a low mass fragment. Finally, the following seven
CpG sites (CpG1, CpG2, CpG3, CpG5, CpG6.7, CpG
8.9, and CpG11.12) were analyzed for differences in
methylation [12].
Statistical analysis
We performed paired analysis to assess the change in global
DNA (hydroxy)methylation over the first 3months using
paired-sample t tests. Associations between global DNA
(hydroxy)methylation at baseline, at 3months and over 3
months (Δ(hydroxy)methylation) with response (ΔDAS28-
ESR) were first analyzed in a univariate linear regression
model, after which the associations were adjusted for con-
founders. Baseline DAS28 score, baseline erythrocyte folate
levels, BMI, age, sex, and smoking status (current versus
former + never) are known to be associated with MTX
response and DNA methylation and were therefore tested
as confounders [13–16]. The presence of anti-citrullinated
protein antibodies (ACPA) has previously been related to
decreased MTX response [17]. ACPA positivity was there-
fore tested as potential covariate. Confounders and covari-
ates were only considered important when the effect size
(beta coefficient, B) changed with > 10% upon adjustment.
In addition, the relation between baseline global DNA
methylation and MTX response was assessed dichotom-
ously (non-responders versus moderate/good responders),
according to the EUropean League Against Rheumatism
(EULAR) response criteria at 3months [18]. Associations
between global DNA methylation and response were
assessed in a crude logistic regression model and in a model
adjusted for baseline DAS28, baseline erythrocyte folate,
and BMI. Results are expressed in odds ratios (OR) with
95% confidence interval (CI). Incomplete cases were
excluded prior to the analysis. For the correlation analysis,
distributions of the variables were tested for normality
using the Shapiro-Wilkinson test, where p > 0.05 was
considered normally distributed. The correlation between
baseline erythrocyte folate and global DNA methylation
was tested using Spearman’s correlation due to the skewed
distribution of erythrocyte folate, and the correlation
between global DNA methylation determined by LC-ESI-
MS/MS and LINE-1 was tested using Pearson’s correlation
test (normally distributed variables). All statistical analyses
were conducted using R Studio Software (Version 1.1.423;
RStudio Team 2015), and p values< 0.05 were considered
significant. Models tested for both methylation and hydro-
xymethylation were corrected for multiple comparisons
using the Bonferroni correction, where p < 0.025 (0.05/2 =
0.025) was considered significant. LINE-1 analysis was cor-
rected using the Bonferroni correction for the 7 CpGs that
were tested simultaneously; hence, p < 0.007 (0.05/7 =
0.007) was considered significant.
Results
Subject baseline characteristics
Genomic DNA was available and isolated from leuko-
cytes of 265 treatment-naive early RA patients and from
275 subjects at T3. A minimum of 600 ng was required
for reliable (hydroxy)methylation measurements. Nine
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(T0) and five (T3) extracted DNA samples did not reach
up to this minimum and were therefore excluded. Global
DNA (hydroxy)methylation was successfully quantified in
294 patients, comprising 249 (T0) and 257 (T3) samples.
Baseline characteristics of these 294 subjects are summa-
rized in Table 1. The mean age was 53.4 ± 14.2 years, and
70.4% was female. Mean DAS28 at baseline was 4.7 ± 1.2
and decreased to 3.0 ± 1.2 over the first 3months (Table 1)
. All patients were treatment naive at baseline and
received MTX mono- or combination therapy for at least
3months (Table 1).
Global DNA hydroxymethylation increases during three
months of MTX therapy
Mean global DNA methylation at baseline was 4.41 ±
0.13% and did not change significantly over the first 3
months of therapy (p = 0.454) (Additional file 1: Table
S1). Global DNA hydroxymethylation increased signifi-
cantly with 0.0008% over the first 3 months (p = 0.013;
Additional file 1: Table S1).
Higher baseline global DNA methylation is associated
with MTX non-response at 3 months
Baseline global DNA methylation was associated with
ΔDAS28 over the first 3 months when assessed in a
crude univariate linear regression model (B = 1.36, p =
0.044). One percent difference in global DNA
methylation at baseline corresponds to 1.41 difference in
ΔDAS28 between patients, when adjusted for baseline
DAS28, baseline erythrocyte folate, and BMI (B = 1.41,
p = 0.013; Table 2).
In addition, we stratified subjects accordingly: non- and
moderate/good responders according to the EULAR
response criteria at 3months.
Higher baseline global DNA methylation was associated
with EULAR non-response in both a crude logistic model
(OR = 0.027, 95% CI = 0.002–0.377) and when adjusted for
baseline DAS28, baseline erythrocyte folate, and BMI
(OR = 0.010, 95% CI = 0.001–0.188; Fig. 1).
Baseline global DNA hydroxymethylation was not sig-
nificantly associated with ΔDAS28 in a crude univariate
model (B = 19.56, p = 0.288), nor when adjusted for base-
line DAS28, baseline erythrocyte folate, BMI, age, and
sex (B = 6.90, p = 0.664; Table 2) and was therefore not
further assessed between non-responders and moderate/
good responders.
As folate is related to DNA methylation through one-
carbon metabolism, we examined the correlation between
baseline global DNA methylation and erythrocyte folate.
We did not observe a correlation between baseline global
DNA methylation and baseline erythrocyte folate concen-
trations (R = 0.084, p = 0.24).
(Change in) global DNA methylation at 3months is not
associated with disease activity
Global DNA methylation at 3months of therapy was not
associated with ΔDAS28 (B = 0.40, p = 0.471), nor was glo-
bal DNA hydroxymethylation at 3months (B = 12.52, p =
0.517; Table 2). In addition, differences between DNA (hy-
droxy)methylation at baseline and after 3months of therapy
were not associated with changes in DAS28 (Δmethylation
B = − 0.68, p = 0.182, Δhydroxymethylation B = − 1.55, p =
0.925; Table 3).
Higher LINE-1 methylation associated with decreased
MTX response
LINE-1 global DNA methylation was determined in
DNA isolated from leukocytes of 120 patients and was
successfully quantified in 104 subjects. Seventy-eight in-
dividuals had no missing data in any of the variables
needed in the analysis and were therefore used. LINE-1
methylation in CpG2 was not significantly associated
with ΔDAS28 in a crude univariate model (B = 0.09, p =
0.242). However, it was associated with ΔDAS28 when
adjusted for baseline DAS28, baseline erythrocyte folate,
BMI, and smoking status (B = 0.16, p = 0.026; Table 4).
Methylation at the other 6 CpG sites within LINE-1 was
not associated with DAS28 nor was mean LINE-1
methylation (Additional file 1: Table S2).
Furthermore, we examined the correlation between
global DNA methylation obtained with LC-ESI-MS/MS
Table 1 Baseline characteristics of early RA patients from the
tREACH
Mean ± SD
Patients, N 294
Male, N (%) 87.0 (29.6%)
Age (years) 53.4 ± 14.2
DAS28 score 4.7 ± 1.2
DAS28 score 3 months* 3.0 ± 1.2
Erythrocyte folate (nmol/L)* 936.0 ± 356.2
BMI (kg/m2)* 26.3 ± 5.1
Smoking status*
Current, N (%) 91.0 (31.0%)
Never + former, N (%) 180.0 (61.2%)
ACPA status
Positive, N (%) 193 (65.6%)
Treatment groups
MTX, N (%) 54.0 (18.4%)
MTX + prednisone p.o., N (%) 81.0 (27.6%)
MTX + SSZ + HCQ + prednisone p.o., N (%) 83.0 (28.2%)
MTX + SSZ + HCQ + corticosteroids i.m., N (%) 76.0 (25.9%)
Abbreviations: SD standard deviation, SSZ sulfasalazine, HCQ
hydroxychloroquine, BMI body mass index, p.o. per os, i.m. intramuscular
*Data was missing for DAS28 score at T3 (n = 10), baseline erythrocyte folate
(n = 75), BMI (n = 3), and smoking status (n = 23)
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and global DNA methylation in CpG2 assessed with the
LINE-1 method. Here, we found a significantly positive
correlation, although not strong (R = 0.34, p = 0.00061;
Additional file 1: Fig. S1).
Association baseline global DNA methylation and non-
response strongest in MTX monotherapy group
To assess whether the association between baseline glo-
bal DNA methylation and disease activity was specific
for MTX response and not due to combination therapy,
subjects were stratified by therapy and univariate linear
regression analyses were performed. The effect size was
1.8-fold higher in the MTX monotherapy group (B =
2.06, p = 0.074) compared to the triple therapy group
(B = 1.12, p = 0.173), although the associations were not
significant (Table 5).
Discussion
In this study, we examined the association between glo-
bal DNA (hydroxy)methylation, before-, at 3 months,
and over 3months of MTX therapy, in relation to changes
in disease activity in leukocytes of eRA patients. We
showed that higher baseline global DNA methylation is as-
sociated with clinical non-response, determined at 3
months of MTX treatment. This is in line with our hypoth-
esis that higher baseline global DNA methylation levels are
more difficult to inhibit and that this is associated with
non-response. Furthermore, mean global DNA methyla-
tion did not change during MTX treatment, and global
DNA methylation at and over 3months was not associated
with clinical efficacy. To our knowledge, we are the first to
report an association between baseline global DNA methy-
lation and early MTX response in eRA patients.
To predict response, associations prior to treatment
are most suitable. Very few studies examined global
DNA methylation status prior to treatment in relation to
MTX response. Glossop and colleagues have identified
21 differentially methylated CpG sites in T-lymphocytes
of 46 treatment-naive early RA patients. Of these, a
combination of 1 hyper- and 1 hypomethylated CpG site
Table 2 Associations between baseline global DNA (hydroxy)methylation and ΔDAS28 before and after 3 months of therapy
Methylation Before MTX After MTX
B (SE) β p B (SE) β p
1 Methylation 1.36 (0.67) 0.15 0.044 0.40 (0.55) 0.05 0.471
2 Methylation 1.41 (0.56) 0.15 0.013 0.44 (0.47) 0.06 0.385
DAS28 − 0.51 (0.06) − 0.49 < 0.001 − 0.50 (0.06) − 0.49 < 0.001
Erythrocyte folate (nmol/L) − 1.00 × 10−3 (2.00 × 10−4) − 0.17 0.006 − 4.00 × 10−4 (2.00 × 10−4) − 0.12 0.063
BMI (kg/m2) 0.03 (0.02) 0.14 0.025 0.04 (0.02) 0.18 0.005
Age (years) – –
Sex – 0.27 (0.16) 0.11 0.098
Smoking (current) – 0.28 (0.16) 0.11 0.084
ACPA status (positive) – –
Observations 181 179
Hydroxymethylation Before MTX After MTX
B (SE) β p B (SE) β p
1 Hydroxymethylation 19.56 (18.38) 0.08 0.288 12.52 (19.26) 0.05 0.517
2 Hydroxymethylation 6.90 (15.89) 0.03 0.664 5.92 (16.75) 0.02 0.724
DAS28 − 0.54 (0.07) − 0.52 < 0.001 − 0.52 (0.07) − 0.51 < 0.001
Erythrocyte folate (nmol/L) − 1.00 × 10−3 (2.00 × 10−4) − 0.18 0.007 −5.00 × 10−4
(2.00 × 10−4)
− 0.14 0.035
BMI (kg/m2) 0.03 (0.02) 0.12 0.062 0.04 (0.02) 0.18 0.006
Age (years) 0.01 (0.01) 0.10 0.125 0.01 (0.01) 0.13 0.057
Sex 0.22 (0.17) 0.08 0.176 0.28 (0.16) 0.11 0.087
Smoking (current) – 0.28 (0.16) 0.11 0.090
ACPA status (positive) – –
Observations 181 177
Association between mean % global DNA (hydroxy)methylation and ΔDAS28 were tested in a crude univariate model (1) and adjusted for potential confounders
(2). Potential confounders were baseline DAS28 score, baseline erythrocyte folate levels (nmol/L), BMI (kg/m2), age (years), sex, smoking status (current smoker
versus former + never smoker), and ACPA status. Only biomarkers that changed the association with > 10% were considered confounders. B beta coefficient, SE
standard error, β standardized beta coefficients. p < 0.05 was considered significant
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gave the strongest predictive value [15]. A second study,
in which 450k methylation arrays were performed, iden-
tified 2 baseline differentially methylated positions be-
tween 36 non-responders and 36 good responders that
were associated with changes in c-reactive protein, but
not with the complete DAS28 score [19].
Changes in global DNA methylation upon treatment
were examined to give us more insight in the underlying
mechanism. Despite the fact that MTX inhibits the uni-
versal methyl donor SAM, MTX administration has
been shown to lead to increased global DNA methyla-
tion in peripheral blood mononuclear cells (PBMCs) of
eRA patients [7, 20]. In contrast, we did not find signifi-
cant methylation changes in leukocytes over the first 3
months. In our study, DNA was isolated from unsorted
peripheral leukocytes. Leukocytes are a cell mixture of
polymorphonuclear cells (PMN) and PBMCs, which
have different methylomes. Changes in DNA methyla-
tion in PBMCs therefore might have been oversha-
dowed, which possibly explains the different results
between these and our study. In addition, in our study,
all subjects were supplemented with folic acid, which
stimulates methyl-group donation. In contrast to global
DNA methylation, we did observe a small, but signifi-
cant increase in global DNA hydroxymethylation during
the first 3 months of therapy. Future studies are neces-
sary to assess this observed effect of MTX on global
DNA hydroxymethylation.
Previously, we demonstrated that lower baseline
erythrocyte folate concentration was associated with
non-response at 3 months [14]. Assuming that erythro-
cyte folate concentrations reflect folate concentrations in
leukocytes, and knowing that folate donates one-carbon
groups required for methylation reactions, a correlation
with baseline DNA methylation was expected, despite
Fig. 1 Higher mean (± SD) baseline global DNA methylation in
EULAR non-responders compared to moderate/good responders.
Response was determined according to the EULAR response criteria
at 3 months. The p value is the result of a logistic regression analysis
between baseline global DNA methylation and EULAR response
criteria adjusted for baseline DAS28, baseline erythrocyte folate, and
BMI. *P<0.05 was considered significant
Table 3 Associations between changes in (hydroxy)methylation and in DAS28 over the first 3 months of therapy
ΔMethylation ΔHydroxymethylation
Biomarkers B (SE) β p B (SE) β p
1 Δ(hydroxy)methylation − 0.50 (0.60) − 0.07 0.403 − 9.32 (19.40) − 0.04 0.632
2 Δ(hydroxy)methylation − 0.68 (0.51) − 0.09 0.182 − 1.55 (16.35) − 0.01 0.925
DAS28 − 0.51 (0.07) − 0.51 < 0.001 − 0.52 (0.07) − 0.51 < 0.001
Erythrocyte folate (nmol/L) − 1.00 × 10−3 (2.00 × 10−4) − 0.15 0.027 − 1.00 × 10−3 (2.00 × 10−4) − 0.16 0.024
BMI (kg/m2) 0.05 (0.03) 0.19 0.005 0.04 (0.02) 0.18 0.008
Age (years) 0.01 (0.01) 0.10 0.134 0.01 (0.01) 0.11 0.130
Sex – 0.20 (0.17) 0.08 0.240
Smoking (current) 0.29 (0.17) 0.11 0.086 0.28 (0.17) 0.11 0.101
ACPA status (positive) – –
Observations 163 161
Associations were tested using crude univariate models (1) and adjusted for confounders (2). Potential confounders were baseline DAS28 score, baseline
erythrocyte folate levels (nmol/L), BMI (kg/m2), age (years), sex, smoking status (current smoker versus former + never smoker), and ACPA status. Only biomarkers
that changed the effect size with > 10% were considered confounders. B beta coefficient, SE standard error, β standardized beta coefficient. p < 0.05 was
considered significant
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we did not observe a correlation between baseline
erythrocyte folate and baseline global DNA methylation.
Furthermore, from the adjusted beta values in our
model, we observed that baseline erythrocyte folate and
global DNA methylation both explained ~ 15% of vari-
ation in DAS28, although the associations were in
opposing directions. In addition, upon adjustment of the
model for confounders, which included erythrocyte
folate, we showed that the positive association between
global DNA methylation and DAS28 is independent
from baseline erythrocyte folate concentration.
According to the EULAR response criteria, response to
therapy is determined at 6months. However, the tREACH
study is designed to produce the greatest treatment differ-
ences during the first 3 months of therapy [8], which is
why we examined response over the first 3months of
therapy. Upon stratification by treatment, the association
between baseline global DNA methylation and DAS28
was strongest in the MTX monotherapy group, despite
the fact that this group was the smallest. This suggests
that the association is regulated through MTX treatment.
The associations upon stratification were not significant,
which was probably due to a loss of power.
Strength of this study is that all patients received the
same MTX dose due to the prospective study design of
the tREACH. Moreover, DNA methylation and hydroxy-
methylation were quantified for each patient simultan-
eously with the same technique. Furthermore, the
association between global DNA methylation and
changes in disease activity upon MTX treatment were
validated with a second technique. Limitations are that
the majority of the patients received MTX-combination
therapy and that the group size for LINE-1 methylation
was limited, thus replication in larger MTX monother-
apy studies is required. In addition, it would be interest-
ing to examine DNA methylation in sorted peripheral
blood leukocytes.
Conclusions
In this paper, we showed that global DNA methylation is
independently associated with disease activity over the
first 3 months of MTX therapy. However, the underlying
pathway, as well as the potential added value of global
DNA methylation in a prediction model for MTX re-
sponse requires further exploration.
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